Research is often lauded for finding life-saving treatments for diseases like cancer or diabetes. But consider the impact of preventing such illnesses from developing in the first place. It’s hard to describe the value of stopping illness or injury from happening. Yet that’s the goal of research on preventive care.
Most Kaiser Permanente Washington scientists study prevention, whether their work focuses on promoting health by influencing individual behavior, building sound prevention services into everyday clinical care, designing smart health coverage, or all three. By conducting their research at Kaiser Permanente Washington—which combines care and coverage—our researchers have access to data from a large, stable population over time, allowing them to discover which approaches to prevention work best.
Examples include research in areas such as:
A team of researchers at Kaiser Permanente Washington Health Research Institute (KPWHRI) produces reviews of scientific evidence that policymakers at the Centers for Medicare & Medicaid Services and the U.S. Preventive Services Task Force and others use in health care decision-making. We do this work as part of the Kaiser Permanente Research Affiliates Evidence-based Practice Center, one of 13 centers nationwide that are sponsored by the federal Agency for Healthcare Research and Quality.
We’re improving the safety and effectiveness of vaccines through clinical trials, and we’re monitoring how well each year’s new flu vaccines are working. In addition, we’re studying ways to better inform parents about the benefits and potential harms of childhood vaccines, to improve their uptake.
We’re working on several fronts to help ensure the safety of prescription drugs and other medical treatments. For example, we play a leading role in the Food and Drug Administration’s Sentinel program to monitor the safety of medical products through routinely collected electronic health care data. We’re exploring ways to improve the safety of prescribing opioid pain medications. And we often study the safety of drugs commonly used to prevent chronic conditions like heart disease, cancer, and depression.
Prevention also includes screening to detect disease before symptoms appear, to identify and treat disease at an earlier stage. Our research is improving the effectiveness of cancer screening programs so people get the appropriate tests when needed based on their particular risks. Our research is also aimed at improving clinical screening for behavioral risks such as smoking, suicidal thoughts, alcohol use disorders, and poor eating and exercise habits.
Our research in areas such as smoking cessation, healthy diet, and chronic illness care finds new ways to encourage individuals to adopt and maintain healthier lifestyles. At the same time, we’re exploring ways to reach large populations through the use of phone-based programs, websites, and mobile technologies.
Fairman CM, Kava CM, Beima-Sofie K, Sakhuja M, Masud M, Dias E, Sheng J, Gorzelitz J, Morshed A, Green BB, Skiba MB, Madhivanan P, Parthasarathy N, Hirschey R, Vander Weg MW, Hebert J. Addressing differences in cancer: A framework for synergistic programming in cancer prevention and control. Res Sq [Preprint]. 2024:rs.3.rs-4046415. doi: 10.21203/rs.3.rs-4046415/v1. PubMed
Luce C, Palazzo L, Anderson ML, Carter-Bawa L, Gao H, Green BB, Ralston JD, Rogers K, Su YR, Tuzzio L, Triplette M, Wernli KJ. A pragmatic randomized clinical trial of multilevel interventions to improve adherence to lung cancer screening (The Larch Study): Study protocol. Contemp Clin Trials. 2024 Mar 11;140:107495. doi: 10.1016/j.cct.2024.107495 [Epub ahead of print] PubMed
Hubbard RA, Su YR, Bowles EJ, Ichikawa L, Kerlikowske K, Lowry KP, Miglioretti DL, Tosteson ANA, Wernli KJ, Lee JM. Predicting five-year interval second breast cancer risk in women with prior breast cancer. J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093/jnci/djae063 [Epub ahead of print] PubMed
Head M, Cohn B, Wernli KJ, Palazzo L, Ehrlich K, Matson A, Knerr S. Young women's perspectives on being screened for hereditary breast and ovarian cancer risk during routine primary care. Womens Health Issues. 2024 Mar 5:S1049-3867(24)00004-5. doi: 10.1016/j.whi.2024.01.004. PubMed
Kessler LG, Comstock B, Aiello Bowles EJ, Mou J, Nash MG, Bravo P, Fleckenstein LE, Pflugeisen C, Gao H, Winer RL, Ornelas IJ, Smith C, Neslund-Dudas C, Shetty P. Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design. PLoS One.. 2024 Mar 4;19(3):e0297773. doi: 10.1371/journal.pone.0297773. eCollection 2024. PubMed
Paula Lozano, MD, MPHSenior Investigator; Director, ACT Center |
Katharine A. Bradley, MD, MPHSenior Investigator |
Jessica Chubak, PhDSenior Investigator |
Dori E. Rosenberg, PhD, MPHSenior Investigator |
Karen Wernli, PhDSenior Investigator |
Erin J. Bowles, MPHDirector, Collaborative Science |
Melissa L. Anderson, MSPrincipal Collaborative Biostatistician |
Paula R. Blasi, MPHCollaborative Scientist |
Joseph E. Glass, PhD, MSWAssociate Investigator |
Julie E. Richards, PhD, MPHAssistant Investigator |
Yu-Ru Su, PhDAssociate Biostatistics Investigator |
Annie Hoopes, MD, MPHActing Assistant Investigator |
Pamela A. Shaw, PhD, MSSenior Biostatistics Investigator |
Claire Allen, MPHManager, Collaborative Science |
Nicole M. Gatto, PhD, MPHPrincipal Collaborative Scientist |
Kelsey Stefanik-Guizlo, MPHCollaborative Scientist |
Theresa E. Matson, PhD, MPHCollaborative Scientist |
Meagan C. Brown, PhD, MPHAssistant Investigator |
Nora Henrikson, PhD, MPHAssociate Investigator |